|1.||Mirkin, Bernard L: 2 articles (03/2004 - 05/2003)|
|2.||Rebbaa, Abdelhadi: 2 articles (03/2004 - 05/2003)|
|3.||Chou, Pauline M: 2 articles (03/2004 - 05/2003)|
|4.||Zheng, Xin: 2 articles (03/2004 - 05/2003)|
|5.||Alvira, Cristina M: 1 article (01/2015)|
|6.||Connolly, Andrew J: 1 article (01/2015)|
|7.||Mohr, Friedrich W: 1 article (01/2015)|
|8.||Miller, Miquell O: 1 article (01/2015)|
|9.||Baburamani, Ana A: 1 article (01/2015)|
|10.||Merk, Denis R: 1 article (01/2015)|
03/01/2014 - "Some mice were treated with a combination of G-1 and the pan-caspase inhibitor, quinoline-Val-Asp(Ome)-CH2-O-phenoxy (Q-VD-OPh), 1 hour before stroke. "
04/01/2011 - "PARP-1(-/-) males had smaller infarcts, whereas PARP-1(-/-) females had larger strokes compared with WT. Q-VD-OPh significantly decreased infarct in both WT and PARP-1(-/-) females in both transient and permanent MCAO models, but had no effect in males. "
08/01/2007 - "Therefore, Q-VD-OPH may be a promising therapeutic agent in stroke."
02/01/2007 - "Specific caspase inhibitor Q-VD-OPh prevents neonatal stroke in P7 rat: a role for gender."
08/01/2007 - "Q-VD-OPH reduced ischemic brain damage and stroke-induced programmed cell death in thymus and spleen, decreased susceptibility to post-stroke bacteremia, and improved survival. "
01/01/2015 - "Q-VD-OPh treatment led to a significant reduction in aneurysm size and decreased extracellular matrix degradation in the aortic wall compared with control mice. "
04/01/2010 - "In contrast, administration of Q-VD-OPh starting 7 days after Ang II infusion had no significant impact on aneurysm development. "
01/01/2015 - "As biological proof of concept that early aortic wall apoptosis plays a role in aneurysm development in Marfan syndrome, Fbn1(C1039G/+) mice were treated daily from 2 to 6 weeks with either (1) a pan-caspase inhibitor, Q-VD-OPh (20 mg/kg), or (2) vehicle control intraperitoneally. "
04/01/2010 - "A daily administration of 20 mg/kg per day Q-VD-OPh starting 6 hours before Ang II infusion reduced aneurysm incidence from 83.3% to 16.7% and maximal aortic diameter from 2.43+/-0.29 mm to 1.58+/-0.18 mm. The caspase inhibitor treated mice showed profoundly diminished levels of medial apoptosis and inflammation. "
04/01/2010 - "To understand the role of apoptosis in the pathogenesis of this common vascular disease, we tested the effect of the pan-caspase inhibitor quinoline-Val-Asp-difluorophenoxymethylketone (Q-VD-OPh) on aneurysm formation using a mouse angiotensin II (Ang II) model. "
07/01/2007 - "Q-VD-OPh treatment in burned rats attenuated myocardial caspase expression, prevented burn-related myocardial Na+ loading, attenuated myocyte cytokine responses, and improved myocardial contraction and relaxation. "
07/01/2007 - "Experimental groups included 1) sham burn given vehicle, 400 microl DMSO; 2) sham burn given Q-VD-OPh (6 mg/kg), a highly specific and stable caspase inhibitor, 24 and 1 h prior to sham burn; 3) burn given vehicle, DMSO as above; 4) burn given Q-VD-OPh (6 mg/kg) 24 and 1 h prior to burn. "
|5.||Wounds and Injuries (Trauma)
12/01/2009 - "The neurologic function scores (both the inclined plane performance and motor grading scores) were significantly better in the Q-VD-OPh-treated group than in the trauma-created control group. "
12/01/2009 - "Q-VD-OPh, a pancaspase inhibitor, reduces trauma-induced apoptosis and improves the recovery of hind-limb function in rats after spinal cord injury."
12/01/2009 - "The response to injury and the neuroprotective effects of Q-VD-OPh were investigated by histopathologic examination and terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) 24 hours and 5 days after trauma. "
12/01/2009 - "This study examined the neuroprotective effects of Q-VD-OPh, a pan-caspase inhibitor, in a rat model of SCI. Thirty Wistar albino rats were divided into 3 groups of 10 each: the sham-operated controls (group 1), the trauma-created controls (group 2), and the QVD- OPh-treated rats (group 3). "
|2.||benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone
|3.||salicylhydroxamic acid (SHAM)
|6.||Dimethyl Sulfoxide (DMSO)
|8.||Caspase 3 (Caspase-3)